USA flag logo/image

An Official Website of the United States Government

Development of A Comprehensive Cell-Based Transporter Assay Platform

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93818
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
GM086970
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OPTIVIA BIOTECHNOLOGY, INC.
115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025-3712
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Development of A Comprehensive Cell-Based Transporter Assay Platform
Agency: HHS
Contract: 1R43GM086970-01
Award Amount: $406,969.00
 

Abstract:

DESCRIPTION (provided by applicant): Transporters are a class of more than 300 membrane proteins that regulate how nutrients and drugs enter and leave biological cells. Transporters have validated clinical significance and affect every aspect of drug ADMET (Absorption, Distribution, Metabolism, Elimination and Toxicity). Utilizing the full potentials of transporters open new possibilities of designing safer and more efficacious drugs, through improving drug bioavailability, achieving more targeted tissue di stribution and reducing adverse drug effects due to drug-drug interactions. Existing transporter assay methods are not able to address the rapidly growing demands for more transporter assays in better model systems. We have demonstrated the feasibility of using a novel transient-expression technology for setting up transporter-specific assays in polarized cell monolayers; this approach could significantly reduce time and cost for developing similar assays using conventional methods, therefore, could notably increase the utilities of transporter proteins in drug discovery and development. The Phase I project is designed to thoroughly examine this assay approach, and to develop and characterize functional assays for 10 therapeutically important transporters. O ther advanced assay setups, such as dual-transporter and knock- out/over-expression models, will also be explored during Phase I. Future Phase II project would be to scale up development efforts for building assays for significantly more transporters, and to explore other cell models, such as human primary cultures, in order to build a better transporter assay platform, for improving prediction of drug ADMET properties in the human. Public Health Relevance: Success of this project will benefit public health by facilitating discovery and development of more efficacious drugs for treating various formidable diseases, particularly CNS diseases and cancer, and by improving drug safety through reducing adverse drug effects due to unwanted tissue distribution and drug-drug interactions.

Principal Investigator:

Dallas Bednarczyk

Business Contact:

Yong Huang
yhuang@optiviabio.com
Small Business Information at Submission:

OPTIVIA BIOTECHNOLOGY, INC.
OPTIVIA BIOTECHNOLOGY, INC. 115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025

EIN/Tax ID: 126014876
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No